2-nitro-5-isopropylthiophene | 29481-18-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 2-nitro-5-isopropylthiophene
• 英文别名: 2-Isopropyl-5-nitro-thiophen；2-Nitro-5-propan-2-ylthiophene
• CAS: 29481-18-3
• 化学式: C₇H₉NO₂S
• 分子量: 171.22
• InChiKey: FSUSBZNNXBRQSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  74.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-lithio-2-nitropropane 、 2-nitrothiophene;3-nitrothiophene 以18%的产率得到
  参考文献：
  名称：

  NEWCOMBE P. J.; NORRIS R. K., AUSTRAL. J. CHEM., 1978, 31, NO 11, 2463-2476

  摘要：

  DOI：

文献信息

• ACYL-HYDRAZONE AND OXADIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF
  申请人：Universidade Federal de Santa Catarina

  公开号：US20150191445A1

  公开（公告）日：2015-07-09

  The present invention relates to acyl-hydrazone compounds, in particular 3,4,5-trimethoxyphenyl-hydrazide derivatives, as well as the oxadiazole analogs thereof and other similar compounds, and to the pharmaceutical use of the same for the treatment of various diseases associated with cell proliferation, such as leukemias, including acute lymphoblastic leukemia (ALL), tumours and inflammation. Acyl-hydrazones have been obtained having activity similar to that of the compound used as a standard in experiments (colchicine). The greater selectivity of the compounds according to the invention is an important feature, associated with fewer side effects than the pharmaceuticals used at present in clinical treatments. The synthetised acyl-hydrazones, more particularly the compounds 02 and 07, exhibited important antileukemic activity, which suggests 02 and 07 as candidates to pharmaceutical prototypes, or to pharmaceuticals for the treatment of leukemias, in particular acute lymphoblastic leukemia (ALL), tumours and other proliferative diseases, such as inflammation. The action mechanism of the most active compounds was determined by using DNA microarrays and subsequent tests indicated by the chip, besides selectivity studies in healthy human lymphocytes.

  本发明涉及酰基腙化合物，特别是3,4,5-三甲氧基苯基腙衍生物，以及其噁二唑类似物和其他类似化合物，以及它们在治疗与细胞增殖相关的各种疾病，如白血病（包括急性淋巴细胞白血病（ALL））、肿瘤和炎症方面的药用。已获得具有与实验中使用的化合物（秋水仙碱）相似活性的酰基腙。根据本发明的化合物具有更大的选择性，与目前在临床治疗中使用的药物相比，副作用更少是一个重要特征。合成的酰基腙，尤其是化合物02和07，表现出重要的抗白血病活性，这表明02和07可能成为药物原型的候选，或用于治疗白血病，特别是急性淋巴细胞白血病（ALL）、肿瘤和其他增殖性疾病，如炎症的药物。最活性化合物的作用机制是通过使用DNA微阵列确定的，并且通过芯片指示的后续测试，以及对健康人类淋巴细胞的选择性研究。
• Alkylatlon orientation rules in conjugate addition of grignard reagents to nitropyrrole and nitrothiophene systems
  作者：Roberto Ballini、Giuseppe Bartoli、Marcella Bosco、Renato Dalpozzo、Enrico Marcantoni

  DOI：10.1016/s0040-4020(01)89831-8

  日期：——

  Conjugate addition of various Grignard reagents to 1-alkyl-2-nitropyrroles and to 2-nitrothiophene has been investigated. 1-Alkyl-2-nitropyrroles undergo alkylation at 3 and 5 positions with prevalence of the latter isomer. On the contrary, in 2-nitrothiophene system, formation of the 3-isomer prevails. In both systems, a bulkier Grignard reagent favours the 5-isomer formation. This trend can be reversed

  已经研究了将各种格氏试剂偶联到1-烷基-2-硝基吡咯和2-硝基噻吩上的方法。1-烷基-2-硝基吡咯在3和5位发生烷基化，后一种异构体普遍存在。相反，在2-硝基噻吩系统中，形成了3-异构体。在两种体系中，较大的格利雅试剂都有利于5-异构体的形成。这种趋势可以逆转，由2-硝基吡咯的1-取代基增加空间位阻。1-（三异丙基甲硅烷基）-3-硝基吡咯和3-硝基噻吩仅产生2-异构体。该反应允许通过一锅法而不是经典的多阶段反应来合成2-烷基-3-硝基噻吩和吡咯。
• Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
  申请人：Cheng T. Peter

  公开号：US20070015797A1

  公开（公告）日：2007-01-18

  Compounds are provided which have the structure wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R 1 , R 2 , R 2a , R 2b , R 2c , R 3 , Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

  提供了一些化合物，它们的结构如下：其中Q为C或N，A为O或S，Z为O或键，X为CH或N，R1、R2、R2a、R2b、R2c、R3、Y、x、m和n如此定义，这些化合物可用作抗糖尿病、降脂和抗肥胖药物。
• CATHEPSIN S INHIBITORS
  申请人：Lin Chun-Cheng

  公开号：US20110166141A1

  公开（公告）日：2011-07-07

  Cathepsin S inhibitors having formula (I), (II), (III) or (IV) as shown in the specification. These inhibitors can be used to treat cancer and autoimmune/inflammatory diseases.

  具有(I)、(II)、(III)或(IV)公式的卡特普西林S抑制剂，如规范所示。这些抑制剂可用于治疗癌症和自身免疫/炎症性疾病。
• Hypoxia Activated Drugs Of Nitrogen Mustard Alkylators
  申请人：Lewis Jason

  公开号：US20110190310A1

  公开（公告）日：2011-08-04

  Hypoxia activated drug compounds having a structure of formula (I) are useful in the treatment of cancer and other hyperproliferative diseases.

  具有公式（I）结构的缺氧激活药物化合物在癌症和其他过度增生性疾病的治疗中是有用的。